Skip to content

Reported March 23, 2026

Next report

Aug 12, 2026 (in a month)
EPS estimate-$0.86

Financials

Q4 2025

Income statement

See full
Revenue-
Operating income-$18.7M-97.9%
Net income-$17.6M-100%
EPS (diluted)-$0.81+62.8%

Balance sheet

See full
Cash & equivalents$47.1M-23.7%
Total debt$441.0K-43.4%
Total equity$106.6M+295%
Total assets$117.2M+51.2%

Cash flow

See full
Operating cash flow-$16.8M-118%
CapEx--100%
Free cash flow-$16.8M-117%

Valuation & ratios

Valuation

as of 12/31/25
See full
Market cap$285.77M
Enterprise value$239.16M

Returns & leverage

See full
Debt / equity
Current ratio10.6×-4.4×

Versus estimates

Ask the moment Aardvark Therapeutics, Inc. Common Stock reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did Aardvark Therapeutics, Inc. Common Stock report Q4 2025 earnings?
Aardvark Therapeutics, Inc. Common Stock (AARD) reported Q4 2025 earnings on March 23, 2026.
What were Aardvark Therapeutics, Inc. Common Stock's Q4 2025 revenue and EPS?
Aardvark Therapeutics, Inc. Common Stock reported revenue of - and diluted EPS of $-0.81 for Q4 2025.
Did Aardvark Therapeutics, Inc. Common Stock beat estimates in Q4 2025?
EPS beat the consensus estimate of $-0.83 by $0.02.
How did Aardvark Therapeutics, Inc. Common Stock's Q4 2025 results compare year-over-year?
Compared to the same quarter a year prior, diluted EPS declined 19.1% from $-0.68.
Where can I find Aardvark Therapeutics, Inc. Common Stock's Q4 2025 SEC filings?
You can read the 8-K earnings release (0001193125-26-119727) and the 10-K periodic report (0001193125-26-119770) directly on SEC EDGAR. The filing index links above go to sec.gov.